Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from GlaxoSmithKline ( (GSK) ).
On 19 March 2026, GSK announced that the U.S. Food and Drug Administration approved Lynavoy (linerixibat), an ileal bile acid transporter inhibitor, as the first medicine in the U.S. specifically indicated for cholestatic pruritus in adults with primary biliary cholangitis, a rare autoimmune liver disease. The decision, underpinned by positive phase III GLISTEN trial data and orphan drug designations, marks GSK’s first liver therapy approval, strengthens its position in hepatology just days after agreeing to license global rights to linerixibat to Alfasigma, and could significantly improve quality of life for PBC patients as regulatory reviews continue in Europe, the U.K., Canada and China.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company that develops and commercialises prescription medicines and vaccines, with a growing focus on immune‑mediated and liver diseases. The group is extending its inflammation expertise into hepatology, advancing a pipeline that targets chronic hepatitis B and steatotic liver disease, including metabolic dysfunction-associated steatohepatitis and alcohol-associated liver disease.
Average Trading Volume: 5,275,318
Technical Sentiment Signal: Buy
Current Market Cap: $104.8B
See more data about GSK stock on TipRanks’ Stock Analysis page.